Corey Pelletier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Corey Pelletier has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Anna Forsythe
Purple Squirrel Economics, New York, NY
3 shared publications - Gabriel Tremblay
Purple Squirrel Economics, New York, NY, USA
3 shared publications - Ajai Chari
Department of Hematology/Oncology, University of California San Francisco, San Francisco, California, USA
1 shared publication - Andrew Briggs
Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
1 shared publication - Arianna Kee
Bristol-Myers Squibb, Summit, NJ, USA
1 shared publication Barbara H. Johnson
IBM Watson Health, Cambridge, MA, USA
1 shared publication
Latest Publications
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1072: COMPARATIVE EFFICACY OF HELICOBACTER PYLORI ERADICATION THERAPIES: A NETWORK META-ANALYSIS
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Tu1072: COMPARATIVE EFFICACY OF HELICOBACTER PYLORI ERADICATION THERAPIES: A NETWORK META-ANALYSIS
- Open Access
- 2 December 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (5) , 503-515
Real-World Treatment Patterns, Healthcare Use and Costs in Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Patients in the USA
Aim: To estimate treatment patterns and healthcare costs among triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Materials & methods: Eligible patients had ≥1 line of t... Lay abstract Treatment of multiple myeloma (MM) has evolved rapidly over recent decades, with the introduction of immunomodulatory drugs, proteasome inhibitors and the anti-CD38 monoclonal antibody...
- 2 December 2020
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (5) , 503-515
Open AccessReal-World Treatment Patterns, Healthcare Use and Costs in Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Patients in the USA
Aim: To estimate treatment patterns and healthcare costs among triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Materials & methods: Eligible patients had ≥1 line of t... Lay abstract Treatment of multiple myeloma (MM) has evolved rapidly over recent decades, with the introduction of immunomodulatory drugs, proteasome inhibitors and the anti-CD38 monoclonal antibody...
- 1 November 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (11) , 2136-2147.e3
Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis
- 1 November 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (11) , 2136-2147.e3
Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis
- Open Access
- 1 November 2019
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 8 (15) , 1265-1298
A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritis
Aim: Indirect treatment comparisons are used when no direct comparison is available. Comparison networks should satisfy the transitivity assumption, that is, equal likelihood of treatment assignment for a given patient based on comparability of studies. Materials & methods: Seven criteria were evaluated across 18 randomized controlled trials in psoriatic arthritis: inclusion/exclusion criteria, clinical trial design and follow-up, patient-level baseline characteristics, disease severity, prior therapies, concomitant and extended-trial treatment and placebo response differences. Results: Across studies, placebo was a common comparator, and key efficacy end points were reported. Collectively, several potential sources of insufficient transitivity were identified, most often related to trial design and population differences. Conclusion: Potential challenges in satisfying transitivity occur frequently and should be evaluated thoroughly.
- 1 November 2019
- Published by Becaris Publishing Limited in Journal of Comparative Effectiveness Research
- Vol. 8 (15) , 1265-1298
Open AccessA criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritis
Aim: Indirect treatment comparisons are used when no direct comparison is available. Comparison networks should satisfy the transitivity assumption, that is, equal likelihood of treatment assignment for a given patient based on comparability of studies. Materials & methods: Seven criteria were evaluated across 18 randomized controlled trials in psoriatic arthritis: inclusion/exclusion criteria, clinical trial design and follow-up, patient-level baseline characteristics, disease severity, prior therapies, concomitant and extended-trial treatment and placebo response differences. Results: Across studies, placebo was a common comparator, and key efficacy end points were reported. Collectively, several potential sources of insufficient transitivity were identified, most often related to trial design and population differences. Conclusion: Potential challenges in satisfying transitivity occur frequently and should be evaluated thoroughly.
- 1 November 2015
- Published by Elsevier in Value in Health
- Vol. 18 (7) , A435
Matching-Adjusted Indirect Treatment Comparison And Survival Extrapolation In Radioiodine-Refractory Differentiated Thyroid Cancer (Rai-Refractory Dtc): Updated Analysis
- 1 November 2015
- Published by Elsevier in Value in Health
- Vol. 18 (7) , A435
Matching-Adjusted Indirect Treatment Comparison And Survival Extrapolation In Radioiodine-Refractory Differentiated Thyroid Cancer (Rai-Refractory Dtc): Updated Analysis
- 1 May 2015
- Published by Elsevier in Value in Health
- Vol. 18 (3) , A194
Epidemiology And Treatment Of Radioactive Iodine-Refractory Differentiated Thyroid Cancer In The Eu5
- 1 May 2015
- Published by Elsevier in Value in Health
- Vol. 18 (3) , A194
Epidemiology And Treatment Of Radioactive Iodine-Refractory Differentiated Thyroid Cancer In The Eu5